Abstract
Objective. To identify risk factors of relapse in IgG4-related disease (IgG4-RD) during glucocorticoid (GC) tapering. Methods. A total of 27 consecutive patients with IgG4-RD (7 with and 20 without relapse) treated with GC for more than 6 months were enrolled. Baseline characteristics were compared in patients with and without relapse. Longitudinal analysis was also performed. Results. Patients with relapse had significantly higher levels of serum IgG4 (816.0 vs. 346.5 mg/dL, p=0.048) and number of organs involved (5 vs. 3, p=0.008) and lower levels of serum IgA (82 vs. 176 mg/dL, p=0.002) at baseline, compared to patients without relapse. The most useful cut-off value of baseline serum IgG4 to predictive relapse was 813 mg/dl with a sensitivity of 57.1% and a specificity of 95.0%. In longitudinal analysis, serum IgG4 decreased at 6 months after treatment in both groups, but was elevated at relapse in patients with relapse, while remaining low in those without relapse. Conclusion. Higher levels of serum IgG4 at baseline were associated with relapse in IgG4-RD. Re-elevation of serum IgG4 levels during GC treatment reflected disease relapse.
| Original language | English |
|---|---|
| Pages (from-to) | S186-S189 |
| Journal | Clinical and Experimental Rheumatology |
| Volume | 36 |
| Publication status | Published - 2018 Jan 1 |
Fingerprint
Keywords
- Glucocorticoid
- IgG4
- IgG4-related disease
- Relapse
- Risk factor
ASJC Scopus subject areas
- Rheumatology
- Immunology and Allergy
- Immunology
Cite this
Risk factors of relapse following glucocorticoid tapering in IgG4-related disease. / Sasaki, T.; Akiyama, M.; Kaneko, Yuko; Yasuoka, Hidekata; Suzuki, Katsuya; Yamaoka, Kunihiro; Takeuchi, Tsutomu.
In: Clinical and Experimental Rheumatology, Vol. 36, 01.01.2018, p. S186-S189.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Risk factors of relapse following glucocorticoid tapering in IgG4-related disease
AU - Sasaki, T.
AU - Akiyama, M.
AU - Kaneko, Yuko
AU - Yasuoka, Hidekata
AU - Suzuki, Katsuya
AU - Yamaoka, Kunihiro
AU - Takeuchi, Tsutomu
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Objective. To identify risk factors of relapse in IgG4-related disease (IgG4-RD) during glucocorticoid (GC) tapering. Methods. A total of 27 consecutive patients with IgG4-RD (7 with and 20 without relapse) treated with GC for more than 6 months were enrolled. Baseline characteristics were compared in patients with and without relapse. Longitudinal analysis was also performed. Results. Patients with relapse had significantly higher levels of serum IgG4 (816.0 vs. 346.5 mg/dL, p=0.048) and number of organs involved (5 vs. 3, p=0.008) and lower levels of serum IgA (82 vs. 176 mg/dL, p=0.002) at baseline, compared to patients without relapse. The most useful cut-off value of baseline serum IgG4 to predictive relapse was 813 mg/dl with a sensitivity of 57.1% and a specificity of 95.0%. In longitudinal analysis, serum IgG4 decreased at 6 months after treatment in both groups, but was elevated at relapse in patients with relapse, while remaining low in those without relapse. Conclusion. Higher levels of serum IgG4 at baseline were associated with relapse in IgG4-RD. Re-elevation of serum IgG4 levels during GC treatment reflected disease relapse.
AB - Objective. To identify risk factors of relapse in IgG4-related disease (IgG4-RD) during glucocorticoid (GC) tapering. Methods. A total of 27 consecutive patients with IgG4-RD (7 with and 20 without relapse) treated with GC for more than 6 months were enrolled. Baseline characteristics were compared in patients with and without relapse. Longitudinal analysis was also performed. Results. Patients with relapse had significantly higher levels of serum IgG4 (816.0 vs. 346.5 mg/dL, p=0.048) and number of organs involved (5 vs. 3, p=0.008) and lower levels of serum IgA (82 vs. 176 mg/dL, p=0.002) at baseline, compared to patients without relapse. The most useful cut-off value of baseline serum IgG4 to predictive relapse was 813 mg/dl with a sensitivity of 57.1% and a specificity of 95.0%. In longitudinal analysis, serum IgG4 decreased at 6 months after treatment in both groups, but was elevated at relapse in patients with relapse, while remaining low in those without relapse. Conclusion. Higher levels of serum IgG4 at baseline were associated with relapse in IgG4-RD. Re-elevation of serum IgG4 levels during GC treatment reflected disease relapse.
KW - Glucocorticoid
KW - IgG4
KW - IgG4-related disease
KW - Relapse
KW - Risk factor
UR - http://www.scopus.com/inward/record.url?scp=85055615616&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055615616&partnerID=8YFLogxK
M3 - Article
C2 - 29846165
AN - SCOPUS:85055615616
VL - 36
SP - S186-S189
JO - Clinical and Experimental Rheumatology
JF - Clinical and Experimental Rheumatology
SN - 0392-856X
ER -